Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633243 · ClinicalTrials.gov registry record · NA
Effective Treatment of Hepatitis C in Substance Users
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT00633243 is a NA study that has completed, run by Yale University. The registered enrollment target is 21 participants.
The verdict
NCT00633243, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
We hypothesize that integrating Hepatitis C into methadone and buprenorphine treatment will improve Hepatitis C outcomes as well as drug treatment outcomes in patients who are addicted to opiates. We will test this hypothesis by randomly assigning patients to receive integrated or separated care. The first group will receive Hepatitis C treatment and substance abuse treatment contemporaneously at the South Central Rehabilitation Center (SCRC). They will take both methadone or buprenorphine and Hepatitis C medications under the daily (methadone) or weekly (buprenorphine) observation of a health care provider. The second group will receive substance abuse treatment at SCRC, and go to another facility to receive Hepatitis C treatment services. These participants will take their medications on their own (without observation). We will look at outcomes such as Hepatitis C viral loads, adherence to medications, and drug treatment outcomes such as receipt of buprenorphine and methadone and urine toxicology testing.
Interventions
- PROCEDURE Modified Directly Observed Therapy (mDOT)
- PROCEDURE Self-Administered Therapy (SAT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633243
The ClinicalTrials.gov registry entry for NCT00633243 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Modified Directly Observed Therapy (mDOT) is the first listed.
NCT00633243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633243 about?
NCT00633243 is a clinical study titled "Effective Treatment of Hepatitis C in Substance Users". We hypothesize that integrating Hepatitis C into methadone and buprenorphine treatment will improve Hepatitis C outcomes as well as drug treatment outcomes in patients who are addicted to opiates. We will test this hypothesis by randomly assigning patients to receive integrated or separated care. Th...
What is the current status of trial NCT00633243?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2007-04. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00633243?
The interventions under investigation include: Modified Directly Observed Therapy (mDOT) (PROCEDURE), Self-Administered Therapy (SAT) (PROCEDURE).
Who is sponsoring clinical trial NCT00633243?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.